文献速递肝病

非酒精性脂肪性肝病的临床病程及其对临床试验设计的启示

Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
PubMed 文献 · J Hepatol · 2022-07-16

基于明尼苏达州奥姆斯特德县1996至2016年诊断的5123例NAFLD成人回顾性队列,随访至2019年。多状态模型显示NAFLD进展缓慢:15年肝硬化风险3%,代偿性肝硬化4年内首次失代偿风险33%(每年8%),首次失代偿后2年内≥2次失代偿风险48%。代偿性肝硬化临床试验需至少纳入2886例随访>2年才能检出肝脏相关终点相对下降15%。

要点

  • NAFLD人群15年进展至肝硬化风险仅3%,肝脏相关结局仅影响小部分人群。
  • 代偿性肝硬化4年内首次失代偿风险33%(每年8%),首次失代偿后2年内≥2次失代偿风险48%。
  • 代偿性肝硬化试验需至少2886例随访>2年才能检出肝脏相关终点相对下降15%。

核心结论

  • 在这一基于人群、随访长达23年的队列中,NAFLD进展缓慢,肝脏相关结局仅影响小部分人群。
  • 临床试验需大样本量和长随访才能检出肝脏相关终点的下降。

研究设计与样本

  • 回顾性研究,采用前瞻性收集的医疗记录链接系统数据。
  • 纳入1996至2016年间在明尼苏达州奥姆斯特德县按临床、生化和影像学标准诊断的所有NAFLD成人,随访至2019年。
  • 共5123例NAFLD患者,中位年龄52岁,女性占53%,中位随访6.4年(范围1-23年)。
  • 肝脏相关结局和死亡经逐份病历复核确认,采用多状态模型评估进展时间和风险。

主要发现

  • NAFLD进展至肝硬化风险:15年内3%。
  • 代偿性肝硬化进展至首次失代偿风险:4年内33%(每年8%)。
  • 首次失代偿进展至≥2次失代偿风险:2年内48%。
  • 白蛋白、胆红素、非出血性食管静脉曲张和糖尿病是失代偿的独立预测因素。
  • 575例死亡中6%为肝脏相关;代偿性肝硬化临床试验需至少纳入2886例随访>2年才能检出肝脏相关终点相对下降15%。

关键数值与推荐

  • NAFLD至肝硬化:15年风险3%。
  • 代偿性肝硬化至首次失代偿:4年风险33%(每年8%)。
  • 首次失代偿至≥2次失代偿:2年风险48%。
  • 575例死亡中肝脏相关占6%。
  • 代偿性肝硬化试验需至少2886例随访>2年以检出肝脏相关终点相对下降15%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The predicted risk and timeline to progression to liver-related outcomes in the population with NAFLD are not well-characterized. We aimed to examine the risk and time to progression to cirrhosis, hepatic decompensation and death in a contemporary population over a long follow-up period, to obtain information to guide endpoint selection and sample size calculations for clinical trials on NAFLD-related cirrhosis. METHODS: This is a retrospective study of prospectively collected data in a medical record linkage system, including all adults diagnosed with NAFLD between 1996-2016 by clinical, biochemical and radiological criteria in Olmsted County, Minnesota and followed until 2019. Liver-related outcomes and death were ascertained and validated by individual medical record review. Time and risk of progression from NAFLD to cirrhosis to decompensation and death were assessed using multistate modeling. RESULTS: A total of 5,123 individuals with NAFLD (median age 52 years, 53% women) were followed for a median of 6.4 (range 1-23) years. The risk of progression was as follows: from NAFLD to cirrhosis: 3% in 15 years; compensated cirrhosis to first decompensation: 33% in 4 years (8%/year); first decompensation to ≥2 decompensations: 48% in 2 years. Albumin, bilirubin, non-bleeding esophageal varices and diabetes were independent predictors of decompensation. Among the 575 deaths, 6% were liver related. Therapeutic trials in compensated cirrhosis would require enrolment of a minimum of 2,886 individuals followed for >2 years to detect at least a 15% relative decrease in liver-related endpoints. CONCLUSION: In this population-based cohort with 23 years of longitudinal follow-up, NAFLD was slowly progressive, with liver-related outcomes affecting only a small proportion of people. Large sample sizes and long follow-up are required to detect reductions in liver-related endpoints in clinical trials. LAY SUMMARY: For patients with compensated non-alcoholic steatohepatitis-related cirrhosis, the time spent in this state and the risk of progression to decompensation are not well-known in the population. We examined the clinical course of a large population-based cohort over 23 years of follow-up. We identified that adults with compensated cirrhosis spend a mean time of 4 years in this state and have a 10% per year risk of progression to decompensation or death. The risk of further progression is 3-fold higher in adults with cirrhosis and one decompensating event. These results are reflective of placebo arm risks in drug clinical trials and are essential in the estimation of adequate sample sizes.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Allen AM, Therneau TM, Ahmed OT, et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol. 2022. PMID: 35843374. doi:10.1016/j.jhep.2022.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。